Opthea’s Baldwin Gives Update on Clinical Data for OPT-302
Megan Baldwin, PhD, CEO and managing director, Opthea Ltd., introduces OPT-302, a new vehicle for targeting the VEGF pathway and wet age-related macular degeneration (AMD). Baldwin says early clinical trial results are “very encouraging,” particularly in patients who have been treated previously with other drugs.
Participant:
Megan Baldwin
Dr Megan Baldwin is CEO/Managing Director of Opthea Limited and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases.